AIM:To clarify the therapeutic strategies and prognosis factors of primary clear cell carcinoma of the liver(PCCCL) . METHODS:The clinical pathological data of 64 patients with PCCCL treated with hepatectomy in our ho...AIM:To clarify the therapeutic strategies and prognosis factors of primary clear cell carcinoma of the liver(PCCCL) . METHODS:The clinical pathological data of 64 patients with PCCCL treated with hepatectomy in our hospital from January 2000 to January 2006 were analyzed retrospectively.The patients were divided into two groups to make treatment analysis:curative resection only(n=40) ;and curative resection and postoperative chemotherapy with calcium folinate and tegafur(n= 24) .Meanwhile,the PCCCL patients were subdivided into two subgroups on the basis of the proportion of clear cells in the tumor for pathological analysis.There were 36 cases in subgroup A for which the proportion of clear cells was more than 70%,and 28 cases in subgroup B for which the proportion was less or equal to 70%,comparing analysis of median survival time of the counterpart groups.Univariate and multivariate analyses were performed to examine factors that affect-ed clinical prognosis,recurrence and metastasis. RESULTS:Median survival period of the curative surgery group was 38 mo,while the counterpart was 41 mo.Median survival period for group A was 41 mo,while group B was 19 mo.The Kaplan-Meier method showed that capsule formation,preoperative liver function,hepatitis C virus infection,large vascular invasion and multiple tumor occurrences were related to disease-free survival.Cox regression analysis showed that the clear cell ratio,capsule formation,preoperative liver function and large vascular invasion were independent risk factors for overall survival. CONCLUSION:Postoperative chemotherapy has no obvious effect on survival of patients with PCCCL. Clear cell ratio,capsule formation,preoperative liver function,and vascular invasion were independent risk factors for prognosis.展开更多
Objective：This study aimed to analyze clinicopathological and prognostic features of four rare pathological subtypes of primary liver malignancies to make better understanding of their clinical features.Methods：The ...Objective：This study aimed to analyze clinicopathological and prognostic features of four rare pathological subtypes of primary liver malignancies to make better understanding of their clinical features.Methods：The clinicopathological data of 114 patients who were diagnosed with histologically proven four subtypes：clear cell carcinoma（CCC）,giant cell carcinoma（GCC）,sarcomatoid carcinoma（SC）,and combined hepatocellular-cholangiocarcinoma（CHC）between October 1998 and August 2015 were reviewed.Their survival data were compared with those of 908 patients with histologically proven common hepatocellular carcinoma（HCC）（early-and advanced-stage HCC）during the same period.Results：The outcome of the CCC group was better than that of the other three subgroups,and was similar to that of the early-stage HCC group.Also,the smallest tumor size and the highest incidence of pseudocapsule formation were observed in the CCC group.The SC group had the worst outcome among these four subgroups;the prognosis was much poorer than that of any other subgroups,even poorer than that of the advanced-stage common HCC group.No statistical difference was observed between the GCC,CHC and advanced-stage HCC groups on survival analysis.The incidences of tumor vascular emboli,TNM staging and non-radical resection were three risk factors of the prognosis.Conclusions：CCC is a low-degree malignancy and relatively favorably prognostic subtype of HCC.However,GCC,SC,and CHC are three rare high-degree malignancy subtypes of HCC with poor prognosis.展开更多
目的微小RNA（microRNA，miRNA）-21在肾癌组织中高表达，充当癌基因，而大量研究发现血清中特异miRNA与相应的癌组织中表达量趋向一致，而血清标本安全易取。本研究旨在验证血清中miR一21在肾透明细胞癌（renalclear cell carcinoma，c...目的微小RNA（microRNA，miRNA）-21在肾癌组织中高表达，充当癌基因，而大量研究发现血清中特异miRNA与相应的癌组织中表达量趋向一致，而血清标本安全易取。本研究旨在验证血清中miR一21在肾透明细胞癌（renalclear cell carcinoma，cRCC）血清中的表达，术后的变化并探讨其临床应用价值。方法新疆医科大学第一附属医院2013—02—01—2014—07—30收集30例cRCC患者术前血清作为肾癌术前组，平均年龄（52士11）岁。肿瘤直径≤4cm17例，〉4cm13例。Fuhrman分级：Ⅰ～Ⅱ级18例，Ⅲ级12例。对应术后1个月血清作为肾癌术后组。另收集同期该院30例健康体检者血清作为对照组，平均年龄（47±9）岁。利用Real～timePCR技术检测miR-21在肾癌术前组、术后组、对照组血清中的表达量，并分析其临床应用价值。结果对照组血清中miR-21相对表达量为0．70（0．52～3．60），肾癌术前组表达量为8．34（3．66～17．27），肾癌术后组表达量为0．68（0．47～1．07）。与对照组比较，肾癌术前组miR-21表达量显著上调，差异有统计学意义，Z=-4．778，P=0．001；肾癌术后组表达量差异无统计学意义，z=-1．135，P=0．256。与术前组比较，术后组表达量明显下调，差异有统计学意义，z=-3．124，P=0．002。依据miR-21在eRCC患者与健康人血清中表达量不同，利用受试者工作特征受试者工作特征（receiver operating characteristic，ROC）曲线法分析，曲线下面积（area under the curve，AUC）=0．865（95％CI：0．766～0．965，P=0．001），敏感性为77．3％，特异性为96．4％。结论在cRCC患者血清中miR-21呈现高表达，根据R0c分析结果已达到临床应用价值，是cRCC可选的诊断分子标志物。miR-21在切除肿瘤组织后表达量下降，有望用于疗效评估。展开更多
文摘AIM:To clarify the therapeutic strategies and prognosis factors of primary clear cell carcinoma of the liver(PCCCL) . METHODS:The clinical pathological data of 64 patients with PCCCL treated with hepatectomy in our hospital from January 2000 to January 2006 were analyzed retrospectively.The patients were divided into two groups to make treatment analysis:curative resection only(n=40) ;and curative resection and postoperative chemotherapy with calcium folinate and tegafur(n= 24) .Meanwhile,the PCCCL patients were subdivided into two subgroups on the basis of the proportion of clear cells in the tumor for pathological analysis.There were 36 cases in subgroup A for which the proportion of clear cells was more than 70%,and 28 cases in subgroup B for which the proportion was less or equal to 70%,comparing analysis of median survival time of the counterpart groups.Univariate and multivariate analyses were performed to examine factors that affect-ed clinical prognosis,recurrence and metastasis. RESULTS:Median survival period of the curative surgery group was 38 mo,while the counterpart was 41 mo.Median survival period for group A was 41 mo,while group B was 19 mo.The Kaplan-Meier method showed that capsule formation,preoperative liver function,hepatitis C virus infection,large vascular invasion and multiple tumor occurrences were related to disease-free survival.Cox regression analysis showed that the clear cell ratio,capsule formation,preoperative liver function and large vascular invasion were independent risk factors for overall survival. CONCLUSION:Postoperative chemotherapy has no obvious effect on survival of patients with PCCCL. Clear cell ratio,capsule formation,preoperative liver function,and vascular invasion were independent risk factors for prognosis.
基金financially supported by the State Key Project on Infection Diseases of China (No.2018ZX10723204-005)the National Natural Science Foundation of China (No.81672461)+3 种基金the National Hightech R&D (863) Program of China (No.2015AA020408)the Capital Health Research and Development of Special(No.2018-1-4021)the CAMS Innovation Fund for Medical Sciences (CIFMS) (No.2016-I2M-1-001)the CAMS Innovation Fund for Medical Sciences (CIFMS) (No.2017-12M-4-002)
文摘Objective：This study aimed to analyze clinicopathological and prognostic features of four rare pathological subtypes of primary liver malignancies to make better understanding of their clinical features.Methods：The clinicopathological data of 114 patients who were diagnosed with histologically proven four subtypes：clear cell carcinoma（CCC）,giant cell carcinoma（GCC）,sarcomatoid carcinoma（SC）,and combined hepatocellular-cholangiocarcinoma（CHC）between October 1998 and August 2015 were reviewed.Their survival data were compared with those of 908 patients with histologically proven common hepatocellular carcinoma（HCC）（early-and advanced-stage HCC）during the same period.Results：The outcome of the CCC group was better than that of the other three subgroups,and was similar to that of the early-stage HCC group.Also,the smallest tumor size and the highest incidence of pseudocapsule formation were observed in the CCC group.The SC group had the worst outcome among these four subgroups;the prognosis was much poorer than that of any other subgroups,even poorer than that of the advanced-stage common HCC group.No statistical difference was observed between the GCC,CHC and advanced-stage HCC groups on survival analysis.The incidences of tumor vascular emboli,TNM staging and non-radical resection were three risk factors of the prognosis.Conclusions：CCC is a low-degree malignancy and relatively favorably prognostic subtype of HCC.However,GCC,SC,and CHC are three rare high-degree malignancy subtypes of HCC with poor prognosis.
文摘目的微小RNA（microRNA，miRNA）-21在肾癌组织中高表达，充当癌基因，而大量研究发现血清中特异miRNA与相应的癌组织中表达量趋向一致，而血清标本安全易取。本研究旨在验证血清中miR一21在肾透明细胞癌（renalclear cell carcinoma，cRCC）血清中的表达，术后的变化并探讨其临床应用价值。方法新疆医科大学第一附属医院2013—02—01—2014—07—30收集30例cRCC患者术前血清作为肾癌术前组，平均年龄（52士11）岁。肿瘤直径≤4cm17例，〉4cm13例。Fuhrman分级：Ⅰ～Ⅱ级18例，Ⅲ级12例。对应术后1个月血清作为肾癌术后组。另收集同期该院30例健康体检者血清作为对照组，平均年龄（47±9）岁。利用Real～timePCR技术检测miR-21在肾癌术前组、术后组、对照组血清中的表达量，并分析其临床应用价值。结果对照组血清中miR-21相对表达量为0．70（0．52～3．60），肾癌术前组表达量为8．34（3．66～17．27），肾癌术后组表达量为0．68（0．47～1．07）。与对照组比较，肾癌术前组miR-21表达量显著上调，差异有统计学意义，Z=-4．778，P=0．001；肾癌术后组表达量差异无统计学意义，z=-1．135，P=0．256。与术前组比较，术后组表达量明显下调，差异有统计学意义，z=-3．124，P=0．002。依据miR-21在eRCC患者与健康人血清中表达量不同，利用受试者工作特征受试者工作特征（receiver operating characteristic，ROC）曲线法分析，曲线下面积（area under the curve，AUC）=0．865（95％CI：0．766～0．965，P=0．001），敏感性为77．3％，特异性为96．4％。结论在cRCC患者血清中miR-21呈现高表达，根据R0c分析结果已达到临床应用价值，是cRCC可选的诊断分子标志物。miR-21在切除肿瘤组织后表达量下降，有望用于疗效评估。
